


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method for the treatment or prophylaxis of a disease which can be influenced by the binding of a compound formula I to a 5 HT receptor, comprising administering to a subject in need thereof an effective amount of a compound of Use of the compounds of the formula I  
in which

5



X denotes CH or N,  
R<sup>1</sup> denotes H, A, Hal, (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms, CF<sub>3</sub>, NO<sub>2</sub>, CN, C(NH)NOH or OCF<sub>3</sub>,  
R<sup>2</sup> denotes (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms or CF<sub>3</sub>,  
R<sup>3</sup>, R<sup>4</sup> denote H, (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>COH<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>CON(R<sup>5</sup>)<sub>2</sub>,  
(CH<sub>2</sub>)<sub>n</sub>COO(CH<sub>2</sub>)<sub>n</sub>Het (CH<sub>2</sub>)<sub>n</sub>000(CH<sub>2</sub>)<sub>n</sub>Het, CHO, (CH<sub>2</sub>)<sub>n</sub>OR<sup>5</sup>,  
(CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=N-OA, CH<sub>2</sub>CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>NHOA,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Het, (CH<sub>2</sub>)<sub>n</sub>CH=N-Het, (CH<sub>2</sub>)<sub>n</sub>OCOR<sup>5</sup> (CH<sub>2</sub>)<sub>n</sub>000R<sup>5</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OCF<sub>3</sub>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)C(R<sup>5</sup>)HCOOR<sup>5</sup> (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)C(R<sup>5</sup>)H000R<sup>5</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>COH<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)CH<sub>2</sub>COOR<sup>5</sup>  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)CH<sub>2</sub>000R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCOOR<sup>5</sup> CH=CH000R<sup>5</sup>,  
CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>OR<sup>5</sup>  
CH=CHCH<sub>2</sub>0R<sup>5</sup>, CH=CHCH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar,  
(CH<sub>2</sub>)<sub>n</sub>N(COOR<sup>5</sup>)COOR<sup>5</sup> (CH<sub>2</sub>)<sub>n</sub>N(000R)COOR<sup>5</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(CONH<sub>2</sub>)COOR<sup>5</sup> (CH<sub>2</sub>)<sub>n</sub>N(CONH<sub>2</sub>)000R<sup>5</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(CONH<sub>2</sub>)CONH<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>COOR<sup>5</sup>)COOR<sup>5</sup> (CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>

$\text{OOR}_5\text{COOR}^5$ ,  $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^5$   
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{OOR}^5$ ,  $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$ ,  
 $(\text{CH}_2)_n\text{CHR}^5\text{COR}^5$ ,  $(\text{CH}_2)_n\text{CHR}^5\text{COOR}^5$   $(\text{CH}_2)_n\text{CHR}^5\text{OOR}^5$ , or  
 $(\text{CH}_2)_n\text{CHR}^5\text{CH}_2\text{OR}^5$   $(\text{CH}_2)_n\text{CHR}^5\text{CH}_2\text{OR}^5$ ,  
where in each case one of the radicals  $\text{R}^3$  or  $\text{R}^4$  has the meaning H,  
 $\text{R}^5$  denotes H or A  
 $\text{A}$  denotes straight-chain or branched alkyl or cycloalkyl having 2 to 4 C atoms, having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,  
 $\text{Het}$  preferably denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,  
 $\text{Ar}$  denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal,  $\text{OR}^5$   $\text{OR}^5$ ,  $\text{OCOR}^5$ ,  $\text{OOCR}^5$ ,  $\text{COOR}^5$   $\text{COOR}^5$ ,  $\text{CON}(\text{R}^5)_2$ , CN,  $\text{NO}_2$ ,  $\text{NH}_2$ ,  $\text{NHCOR}^5$ ,  $\text{CF}_3$  or  $\text{SO}_2\text{CH}_3$   $\text{SO}_2\text{CH}_3$ ,  
 $n$  denotes 0, 1, 2, 3, 4 or 5, and  
 $\text{Hal}$  denotes F, Cl, Br or I,  
or a salt, solvate, enantiomer or racemate thereof  
and salts and solvates, enantiomers and racemates thereof for the preparation of a medicament for the treatment and prophylaxis of diseases which can be influenced by the binding of the compounds of the formula I to 5-HT receptors.

2. (Currently Amended) Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having A method according to claim 1, wherein the compound of formula I has a 5-HT receptor-antagonistic action.

3. (Currently Amended) Use of compounds according to Claim 4 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having A method according to claim 1, wherein the compound of formula I has a 5-HT<sub>2A</sub> receptor-antagonistic action.

4. (Currently Amended) A method according to claim 1, wherein the disease is Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the prophylaxis and/or treatment of psychoses, a neurological disorder disorders, amyotrophic lateral sclerosis, an eating disorder, disorders, such as bulimia, anorexia nervosa, of premenstrual syndrome and/or for positively influencing or obsessive-compulsive disorder (OCD).

5. (Currently Amended) A method Use of the compounds of the formula I according to claim 1, in which R<sup>1</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl.

6. (Currently Amended) A method Use of the compounds of the formula I according to claim 1, in which R<sup>3</sup> denotes (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>CO-Het, CHO, CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>-Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, or CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>OR<sup>5</sup>, CH=CHCH<sub>2</sub>Het or (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar.

7. (Currently Amended) A method Use of the compounds of the formula I according to claim 1, in which R<sup>4</sup> denotes H.

8. (Currently Amended) A method Use of the compounds of the formula I according to claim 1, in which R<sup>2</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl.

9. (Currently Amended) A method Use of the compounds of the formula I according to claim 1, in which X has the meaning CH.

10. (Cancelled)

11. (New) A method according to claim 1, wherein the compound of formula I is


[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(4-methylpiperazin-1 -yl)amine;  
4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;  
4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;  
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;  
1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;  
1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;  
1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;  
2-[(1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino]ethanol;  
[1 -biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(2-methoxyethyl)amine;  
2-[(1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl)methylamino]ethanol;  
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam;  
1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine; or  
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1 -methylpyrrolidin-3-yl)amine;  
or a salt or solvate thereof.

12. (New) A method according to claim 1, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating

disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

13. (New) A method for the treatment or prophylaxis of a disease which can be influenced by the binding of a compound formula I to a 5 HT receptor, comprising administering to a subject in need thereof an effective amount of a compound of formula I

in which



X	denotes CH or N,
R <sup>1</sup>	denotes H, A, Hal, (CH <sub>2</sub> ) <sub>n</sub> Het, (CH <sub>2</sub> ) <sub>n</sub> Ar, cycloalkyl having 3 to 7 C atoms, CF <sub>3</sub> , NO <sub>2</sub> , CN, C(NH)NOH or OCF <sub>3</sub> ,
R <sup>2</sup>	denotes (CH <sub>2</sub> ) <sub>n</sub> Het, (CH <sub>2</sub> ) <sub>n</sub> Ar, cycloalkyl having 3 to 7 C atoms or CF <sub>3</sub> ,
R <sup>3</sup> , R <sup>4</sup>	denote H, (CH <sub>2</sub> ) <sub>n</sub> CO <sub>2</sub> R <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> COH <sub>2</sub> , (CH <sub>2</sub> ) <sub>n</sub> CON(R <sup>5</sup> ) <sub>2</sub> , (CH <sub>2</sub> ) <sub>n</sub> COO(CH <sub>2</sub> ) <sub>n</sub> Het, CHO, (CH <sub>2</sub> ) <sub>n</sub> OR <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> Het, (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> ) <sub>2</sub> , CH=N-OA, CH <sub>2</sub> CH=N-OA, (CH <sub>2</sub> ) <sub>n</sub> NHOA, (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> )Het, (CH <sub>2</sub> ) <sub>n</sub> CH=N-Het, (CH <sub>2</sub> ) <sub>n</sub> OCOR <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> )CH <sub>2</sub> CH <sub>2</sub> OR <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> )CH <sub>2</sub> CH <sub>2</sub> OCF <sub>3</sub> , (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> )C(R <sup>5</sup> )HCOOR <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> )CH <sub>2</sub> COH <sub>2</sub> , (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> )CH <sub>2</sub> Het, (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> )CH <sub>2</sub> CH <sub>2</sub> Het, (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> )CH <sub>2</sub> CH <sub>2</sub> N(R <sup>5</sup> )CH <sub>2</sub> COOR <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> )CH <sub>2</sub> CH <sub>2</sub> OR <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> )CH <sub>2</sub> CH <sub>2</sub> N(R <sup>5</sup> ) <sub>2</sub> , CH=CHCOOR <sup>5</sup> , CH=CHCH <sub>2</sub> NR <sup>5</sup> Het, CH=CHCH <sub>2</sub> N(R <sup>5</sup> ) <sub>2</sub> , CH=CHCH <sub>2</sub> OR <sup>5</sup> , CH=CHCH <sub>2</sub> Het, (CH <sub>2</sub> ) <sub>n</sub> N(R <sup>5</sup> )Ar, (CH <sub>2</sub> ) <sub>n</sub> N(COOR <sup>5</sup> )COOR <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> N(CONH <sub>2</sub> )COOR <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> N(CONH <sub>2</sub> )CONH <sub>2</sub> , (CH <sub>2</sub> ) <sub>n</sub> N(CH <sub>2</sub> COOR <sup>5</sup> )COOR <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> N(CH <sub>2</sub> CONH <sub>2</sub> )COOR <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> N(CH <sub>2</sub> CONH <sub>2</sub> )CONH <sub>2</sub> , (CH <sub>2</sub> ) <sub>n</sub> CHR <sup>5</sup> COR <sup>5</sup> , (CH <sub>2</sub> ) <sub>n</sub> CHR <sup>5</sup> COOR <sup>5</sup> , or (CH <sub>2</sub> ) <sub>n</sub> CHR <sup>5</sup> CH <sub>2</sub> OR <sup>5</sup> , where in each case one of the radicals R <sup>3</sup> or R <sup>4</sup> has the meaning H,
R <sup>5</sup>	denotes H or A

A denotes straight-chain or branched alkyl having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,  
Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,  
Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR<sup>5</sup>, OCOR<sup>5</sup>, COOR<sup>5</sup>, CON(R<sup>5</sup>)<sub>2</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, NHCOR<sup>5</sup>, CF<sub>3</sub> or SO<sub>2</sub>CH<sub>3</sub>,  
n denotes 0, 1, 2, 3, 4 or 5, and  
Hal denotes F, Cl, Br or I,  
or a salt thereof.

14. (New) A method according to claim 13, wherein the compound of formula I is

[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]- (4-methylpiperazin-1-yl)amine;

4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;

4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;

1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;

1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;

1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;

1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;

N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;

2-{{1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino}ethanol;

[1 -biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]- (2-methoxyethyl)amine;

2-{{1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino}ethanol;

1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam;  
1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine; or  
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1 -methylpyrrolidin-3-yl)amine;  
or a salt thereof.

15. (New) A method according to claim 13, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

16. (New) A method according to claim 14, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

17. (New) A method according to claim 1, in which

$R^1$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,

$R^3$  denotes  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCO-Het$ ,  $CHO$ ,  $CH_2OR^5$ ,  $(CH_2)_n-Het$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$  or  $(CH_2)_nN(R^5)Ar$ ,

$R^4$  denotes H,

$R^2$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or

5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and  
X has the meaning CH.

18. (New) A method according to claim 13, in which  
R<sup>1</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,  
R<sup>3</sup> denotes (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>CO-Het, CHO, CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>-Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>OR<sup>5</sup>, CH=CHCH<sub>2</sub>Het or (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar,  
R<sup>4</sup> denotes H,  
R<sup>2</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and  
X has the meaning CH.

19. (New) A method according to claim 17, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

20. (New) A method according to claim 18, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).